Methylergonovine has 23 known drug interactions based on U.S. FDA drug labeling data. Of these, 13 are contraindicated combinations that should be avoided entirely. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Clarithromycin, Cotrimoxazole, Fluconazole. Patients taking Methylergonovine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 23
- Contraindicated
- 13
- Major
- 1
- Moderate
- 9
Contraindicated (13)
- Methylergonovine + Clarithromycin— Macrolide antibiotic and strong CYP 3A4 inhibitor; should not be co-administered due to risk of vasospasm leading to cer…
- Methylergonovine + Cotrimoxazole— Moderate CYP 3A4 inhibitor; should not be co-administered with methylergonovine.
- Methylergonovine + Fluconazole— Moderate CYP 3A4 inhibitor; should not be co-administered with methylergonovine.
- Methylergonovine + Fluvoxamine— Moderate CYP 3A4 inhibitor; should not be co-administered with methylergonovine.
- Methylergonovine + Indinavir— HIV protease inhibitor and strong CYP 3A4 inhibitor; should not be co-administered due to risk of vasospasm leading to c…
- Methylergonovine + Itraconazole— Coadministration is contraindicated. Itraconazole increases plasma concentrations of ergot alkaloids, potentially increa…
- Methylergonovine + Ketoconazole— Coadministration of ketoconazole with methylergometrine is contraindicated.
- Methylergonovine + Nefazodone— Strong CYP 3A4 inhibitor; should not be co-administered due to risk of vasospasm leading to cerebral ischemia and/or isc…
- Methylergonovine + Nelfinavir— HIV protease inhibitor and strong CYP 3A4 inhibitor; should not be co-administered due to risk of vasospasm leading to c…
- Methylergonovine + Ritonavir— HIV protease inhibitor and strong CYP 3A4 inhibitor; should not be co-administered due to risk of vasospasm leading to c…
- Methylergonovine + Saquinavir— Strong CYP 3A4 inhibitor; should not be co-administered due to risk of vasospasm leading to cerebral ischemia and/or isc…
- Methylergonovine + Troleandomycin— Macrolide antibiotic and strong CYP 3A4 inhibitor; should not be co-administered due to risk of vasospasm leading to cer…
- Methylergonovine + Voriconazole— Azole antifungal and strong CYP 3A4 inhibitor; should not be co-administered due to risk of vasospasm leading to cerebra…
Major (1)
- Methylergonovine + Ephedrine Sulfate— Serious postpartum hypertension and stroke reported with concurrent vasopressor and oxytocic use. Carefully monitor bloo…
Moderate (9)
- Methylergonovine + Chlorzoxazone— Weak CYP 3A4 inhibitor; should be administered with caution.
- Methylergonovine + Cilostazol— Weak CYP 3A4 inhibitor; should be administered with caution.
- Methylergonovine + Halothane— Anesthetic that may reduce the oxytocic potency of methylergonovine.
- Methylergonovine + Methoxyflurane— Anesthetic that may reduce the oxytocic potency of methylergonovine.
- Methylergonovine + Nevirapine— Strong CYP 3A4 inducer; likely to decrease the pharmacological action of methylergonovine.
- Methylergonovine + Nitroglycerin— Antianginal drug; methylergonovine produces vasoconstriction and may reduce the effect of glyceryl trinitrate.
- Methylergonovine + Nonselective Beta-Adrenergic Antagonists— Caution advised; concomitant use may enhance the vasoconstrictive action of methylergonovine.
- Methylergonovine + Ranitidine— Weak CYP 3A4 inhibitor; should be administered with caution.
- Methylergonovine + Rifampin— Strong CYP 3A4 inducer; likely to decrease the pharmacological action of methylergonovine.